16 Feb 2017 07:00
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Investor presentation
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it will be hosting investor and analyst presentations in London on Monday 6 March 2017 and in Zürich, Switzerland the following day, Tuesday 7 March 2017.
The presentations will outline some of the key aspects of Advanced Oncotherapy's technology, the clinical benefits of proton therapy and the key milestones for the manufacturing and commercialisation of LIGHT (Linac for Image Guided Hadron Therapy). These events are in relation to the initial 100 day review that has been conducted by CEO Nicolas Serandour, as announced upon his appointment on 27 October 2016.
The event in London will be held at the Royal Society of Medicine, 1 Wimpole St, W1G 0AE.
In Zürich, it will take place at the Baur au Lac hotel, Talstrasse 1, 8001, Switzerland. Both events will commence at 4pm local time and will be followed by drinks and canapés at 5.30pm.
The timetable for the event in London is as follows:
15:30 | Registration
|
16:00 | Introduction to Advanced Oncotherapy: From the Development of a World-Leading Technology to its Commercialisation
|
16:20
| The Benefit of Proton Therapy: How to Make the Best Use of Proton Therapy in Today's Treatments
|
16.35 | The Advantages of the LIGHT System: Taking Advantage of a Linear Accelerator
|
16.50 | Roadmap to Production and Conclusions
|
17.05 | Q&As |
17.30 | Drinks & canapés |
The event in Zürich will follow the same format, excluding registration.
To register and attend either presentation, or to receive further information on Advanced Oncotherapy, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com.
For further information, please contact:
Advanced Oncotherapy plc | www.avoplc.com | ||||
Nicolas Serandour, Chief Executive Officer | Tel: +44 20 3617 8728 | ||||
Michael Sinclair, Executive Chairman | |||||
Stockdale Securities (Nomad & Joint Broker) | Tel: +44 20 7601 6100 | ||||
Antonio Bossi / David Coaten | |||||
Stifel Nicolaus Europe (Joint Broker) | Tel: +44 20 7710 7600 | ||||
| |||||
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com | ||||
Paul McManus | Mob: +44 7980 541 893 | ||||
Anna Dunphy | Mob: +44 7876 741 001 |
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac for Image Guided Hadron Therapy (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Advanced Oncotherapy (AVO)